Screener
Prelude Therapeutics PRLD Q4 2025 Annual earnings
Reported March 10, 2026 · Before market open
Revenue$5.6MMiss by $14.9M
EPS-$0.20Beat by $0.13
Revenue estimate$20.5M
EPS estimate-$0.33
Next report
Nov 11, 2026 (in 2 months)Revenue estimate$35.3M
EPS estimate-$0.16
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Prelude Therapeutics report Q4 2025 earnings?
- Prelude Therapeutics (PRLD) reported Q4 2025 earnings on March 10, 2026 before market open.
- What were Prelude Therapeutics's Q4 2025 revenue and EPS?
- Prelude Therapeutics reported revenue of $5.6M and eps of $-0.20 for Q4 2025.
- Did Prelude Therapeutics beat estimates in Q4 2025?
- Revenue missed the consensus estimate of $20.5M by $14.9M. EPS beat the consensus estimate of $-0.33 by $0.13.
- How did Prelude Therapeutics's Q4 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 40.0% from $4.0M a year earlier and eps grew 47.4% from $-0.38.
- Where can I find Prelude Therapeutics's Q4 2025 SEC filings?
- You can read the 8-K earnings release (0001193125-26-099424) and the 10-K periodic report (0001193125-26-099428) directly on SEC EDGAR. The filing index links above go to sec.gov.
